NeuroMetrix Reports that Quell® Wearable Neuromodulation Device has Received FDA De Novo Authorization as First Non-Pharmacological Treatment for Fibromyalgia
May 19, 2022 09:00 ET
|
NeuroMetrix, Inc.
WOBURN, Mass., May 19, 2022 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today announced U.S. Food and Drug Administration (FDA) De Novo authorization to market the Quell neuromodulation...
Exagen Inc. Reports Fourth Quarter and Full Year 2021 Results
March 22, 2022 16:05 ET
|
Exagen Inc.
SAN DIEGO, March 22, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the fourth quarter and full year...
Exagen Inc. to Participate in the 2022 BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
February 02, 2022 16:05 ET
|
Exagen Inc.
SAN DIEGO, Feb. 02, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced its participation in the BTIG MedTech, Digital Health,...
Chronic Pain Market to Surpass US$ 108,814 Million by 2028, Says Coherent Market Insights (CMI)
November 17, 2021 08:40 ET
|
CMI
SEATTLE, Nov. 17, 2021 (GLOBE NEWSWIRE) -- According to Coherent Market Insights, the global chronic pain market is estimated to be valued at US$ 64,068 million in 2020 and is expected to exhibit a...
Axsome Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Update
November 08, 2021 07:00 ET
|
Axsome Therapeutics, Inc.
Company to host conference call today at 8:00 AM Eastern NEW YORK, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies...
InvestorBrandNetwork Announces The Dealmaker Show Interview with Tryp Therapeutics Inc. CEO Greg McKee
August 03, 2021 08:00 ET
|
InvestorBrandNetwork (IBN)
LOS ANGELES, Aug. 03, 2021 (GLOBE NEWSWIRE) -- via InvestorWire – InvestorBrandNetwork (“IBN”), a multifaceted financial news and publishing company for private and public entities, today announces...
Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Developing Evidence-Based Innovation Where Drugs Are Lacking
July 28, 2021 08:30 ET
|
Tryp Therapeutics Inc.
NEW YORK, July 28, 2021 (GLOBE NEWSWIRE) -- via InvestorWire — Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) today announces its placement in an editorial published by NetworkNewsWire ("NNW"),...
NeuroMetrix Announces Peer-Reviewed Publication of a Randomized Controlled Trial of its Wearable Neurostimulation Technology for Treatment of Fibromyalgia
July 26, 2021 09:00 ET
|
NeuroMetrix, Inc.
WOBURN, Mass., July 26, 2021 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today announced a publication titled “Effects of Wearable Transcutaneous Electrical Nerve Stimulation on...
NeuroMetrix Receives FDA Breakthrough Device Designation for Treatment of Fibromyalgia with its Wearable Neurostimulation Technology
July 20, 2021 09:00 ET
|
NeuroMetrix, Inc.
WOBURN, Mass., July 20, 2021 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today announced that its Quell® device has received Breakthrough Designation from the U.S. Food and Drug...
InvestorBrandNetwork (IBN) Announces Latest Episode of Stock2Me Podcast featuring Tryp Therapeutics Inc. Chairman and CEO Greg McKee
June 17, 2021 08:17 ET
|
InvestorBrandNetwork (IBN)
LOS ANGELES, June 17, 2021 (GLOBE NEWSWIRE) -- (via InvestorWire) InvestorBrandNetwork (“IBN”), a multifaceted communications organization engaged in connecting public companies to the investment...